JPRN-UMIN000004406CompletedPhase 2
ow dose estramustine phosphate against castration-resistant prostate cancer: phase II study - Low dose EMP against CRPC
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Kyoto University Hospital
- Enrollment
- 80
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 85years-old (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Patients who have had estramustine phosphate therapy (including other estrogen-based hormone therapy) 2) Patients with malignancy within 5 years except carcinoma in situ or other malignancies limited within visceral mucosa 3) History of phlebitis, pulmonary embolism, intracranial infarction and coronary diseases 4) History of severe heart disease and renal diseases 5) Patients with active peptic ulcer 6) Psychiatric illness that makes it undesirable for the subject to participate in the trial 7) Evidence of any other significant disorder that make it undesirable for enrollment
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Medical management of refractory mastalgiaCTRI/2021/01/030359All India Institute of Medical Sciences Delhi
Completed
Not Applicable
Treatment of non-responsive breast pain.CTRI/2017/12/010745Intra mural research grant10
Active, not recruiting
Phase 1
Repeated doses of misoprostol for medical treatment of intact miscarriageIntact miscarriage which has not been expelled from the body (missed abortion)EUCTR2011-001505-26-SEKarolinska Institutet899,991
Active, not recruiting
Phase 1
EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT.Women with confirmed high grade serous or endometrial epithelial ovarian cancer.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000693-30-ITENTE OSPEDALIERO OSPEDALI GALLIERA468
Completed
Not Applicable
Clinical study on the efficacy and safety of EstroG-100J for menopausal symptoms: randomized double-blinded controlled studyJPRN-UMIN000015967Tsukuba International Clinical Pharmacology Clinic60